RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease


You May Also Like

Albireo Reports Third Quarter 2017 Financial Results

— Executing towards planned A4250 Phase 3 PFIC trial —— Decision on potential approval of ...

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced ...